Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial

• Published in: The Lancet (British edition) 2019-10, Vol.394 (10205), p.1243-1253
• Main Authors: Iglesias, Juan F, Muller, Olivier, Heg, Dik, Roffi, Marco, Kurz, David J, Moarof, Igal, Weilenmann, Daniel, Kaiser, Christoph, Tapponnier, Maxime, Stortecky, Stefan, Losdat, Sylvain, Eeckhout, Eric, Valgimigli, Marco, Odutayo, Ayodele, Zwahlen, Marcel, Jüni, Peter, Windecker, Stephan, Pilgrim, Thomas
• Format: Article
• Language: English
• Subjects: Allocations; Bayesian analysis; Biodegradability; Biodegradable materials; Biodegradation; Blood vessels; Cardiovascular disease; Chromium; Chromium plating; Clinical outcomes; Clinical trials; Cobalt; Cobalt plating; Conditional probability; Consent; Coronary artery; Coronary artery disease; Coronary vessels; Diabetes mellitus; Drug delivery; Electrocardiography; Failure; Heart; Heart attacks; Heart diseases; Implants; Inhibitor drugs; Ischemia; Lesions; Myocardial infarction; Patients; Physicians; Polymers; Randomization; Rapamycin; Stents; Surgical implants; Thromboembolism; Thrombosis
• ISSN: 0140-6736; 1474-547X
• DOI: 10.1016/S0140-6736(19)31877-X

Newer-generation drug-eluting stents that combine ultrathin strut metallic platforms with biodegradable polymers might facilitate vascular healing and improve clinical outcomes in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention (PCI) compared with contemporary thin strut second-generation drug-eluting stents. We did a randomised clinical trial to investigate the safety and efficacy of ultrathin strut biodegradable polymer sirolimus-eluting stents versus thin strut durable polymer everolimus-eluting stents in patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI. The BIOSTEMI trial was an investigator-initiated, multicentre, prospective, single-blind, randomised superiority trial at ten hospitals in Switzerland. Patients aged 18 years or older with acute STEMI who were referred for primary PCI were eligible to participate. Patients were randomly allocated (1:1) to either biodegradable polymer sirolimus-eluting stents or durable polymer everolimus-eluting stents. Central randomisation was done based on a computer-generated allocation sequence with variable block sizes of 2, 4, and 6, which was stratified by centre, diabetes status, and presence or absence of multivessel coronary artery disease, and concealed using a secure web-based system. Patients and treating physicians were aware of group allocations, whereas outcome assessors were masked to the allocated stent. The experimental stent (Orsiro; Biotronik; Bülach, Switzerland) consisted of an ultrathin strut cobalt–chromium metallic stent platform releasing sirolimus from a biodegradable polymer. The control stent (Xience Xpedition/Alpine; Abbott Vascular, Abbott Park, IL, USA) consisted of a thin strut cobalt–chromium stent platform that releases everolimus from a durable polymer. The primary endpoint was target lesion failure, a composite of cardiac death, target vessel myocardial reinfarction (Q-wave and non-Q-wave), and clinically-indicated target lesion revascularisation, within 12 months of the index procedure. All analyses were done with the individual participant as the unit of analysis and according to the intention-to-treat principle. The trial was registered with ClinicalTrials.gov, number NCT02579031. Between April 26, 2016, and March 9, 2018, we randomly assigned 1300 patients (1623 lesions) with acute myocardial infarction to treatment with biodegradable polymer sirolimus-eluting stents (649 patients and 8